Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2025-11-12 00:00:00 ET · period of report 2025-11-07 · accession 0002001011-25-000097 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-12 | 2025-11-07 | LGND | LAMATTINA JOHN L | Dir | S - Sale+OE | $205.45 | -4,179 | 30.7K | -12% | -$858.6K |
| DM | 2025-11-12 | 2025-11-07 | LGND | LAMATTINA JOHN L | Dir | M - OptEx | $67.78 | +4,179 | 32.8K | +15% | +$283.2K |
| DM | 2025-11-12 | 2025-11-07 | LGND | LAMATTINA JOHN L | Dir | M - OptEx | $0.00 | -4,179 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-07 | S | D | 2,034 | $205.45 | 30,724 | D | — | — | |
| 2 | Common | Common Stock | 2025-11-07 | M | A | 2,145 | $66.13 | 32,869 | D | — | — | |
| 3 | Common | Common Stock | 2025-11-07 | S | D | 2,145 | $205.45 | 30,724 | D | — | — | |
| 4 | Common | Common Stock | 2025-11-07 | M | A | 2,034 | $69.51 | 32,758 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-11-07 | M | D | 2,145 | $0.00 | 0 | D | $66.13 · — to 2027-05-25 | 2,145 Common Stock | (F1) This Option was previously reported as a Grant of 2,456 shares, which vested in full on May 25, 2018, at an exercise price of $113.5000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| 6 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-11-07 | M | D | 2,034 | $0.00 | 0 | D | $69.51 · — to 2026-05-23 | 2,034 Common Stock | (F2) This Option was previously reported as a Grant of 2,329 shares, which vested in full on May 23, 2017, at an exercise price of $119.3000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |